Pulse Entdecken nav.journalClub Debatten Trends Forschende Zeitschriften

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

February 6, 2026Open Access

View Full Paper

Economic burden of non-transfusion-dependent thalassemia in the United States

ALArielle L. LangerBrigham and Women's Hospital ARAmey RaneAgios Pharmaceuticals (United States)KGKeely GilroyAgios Pharmaceuticals (United States)

Key Points

The aim is to evaluate the economic burden of non-transfusion-dependent thalassemia (NTDT) in the United States compared to matched controls.
Analyzed healthcare resource utilization (HCRU) and costs associated with NTDT patients.
Compared NTDT patients to matched controls to assess differences in costs and resource use.
Patients with NTDT exhibited significantly higher all-cause healthcare resource utilization than matched controls.
The overall healthcare costs for NTDT patients were notably elevated compared to the control group.

Abstract

Patients with NTDT in the United States, including those with α- and β-thalassemia, have significantly higher all-cause HCRU and costs vs. matched controls. There is a need for effective treatment options to reduce the healthcare burden of NTDT and improve patient outcomes.

KI fragen

Like

Bookmark

Share

View Full Paper

KI fragen

Like

Bookmark

Share

View Full Paper

Economic burden of non-transfusion-dependent thalassemia in the United States | Synapse

Cite This Study

Langer et al. (Tue,) studied this question.

synapsesocial.com/papers/698584b78f7c464f23008232 https://doi.org/https://doi.org/10.1080/13696998.2026.2618930